GH1 and Behcet disease: Despite no significant differences between the different potential beneficial treatments and the BD group, a high increase in their liver levels was detected in the BD group treated with GH, anti-VEGFR1, and anti-VEGFR2 (the BD + GH + anti-VEGFR1+anti-VEGFR2 group), indicating the strong inflammatory potential of this pathway and a synergism in the inflammatory response of these modulators (Figure 2B).